Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.

Dummer, Reinhard

Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. [electronic resource] - The Lancet. Oncology 10 2018 - 1315-1327 p. digital

Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

1474-5488

10.1016/S1470-2045(18)30497-2 doi


Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols--adverse effects
Benzimidazoles--administration & dosage
Biomarkers, Tumor--genetics
Carbamates--administration & dosage
Disease Progression
Female
Genetic Predisposition to Disease
Humans
Male
Melanoma--drug therapy
Middle Aged
Mutation
Phenotype
Progression-Free Survival
Protein Kinase Inhibitors--administration & dosage
Proto-Oncogene Proteins B-raf--genetics
Skin Neoplasms--drug therapy
Sulfonamides--administration & dosage
Time Factors
Vemurafenib--administration & dosage
Young Adult